SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 64 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2013. The put-call ratio across all filers is 0.67 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $11,379,097 | -21.1% | 425,387 | +0.6% | 0.00% | -33.3% |
Q1 2024 | $14,427,171 | +11.9% | 422,960 | -5.0% | 0.00% | 0.0% |
Q4 2023 | $12,889,067 | +2.5% | 445,372 | -2.3% | 0.00% | 0.0% |
Q3 2023 | $12,569,908 | -8.7% | 455,927 | -0.5% | 0.00% | 0.0% |
Q2 2023 | $13,768,081 | -22.1% | 458,020 | -6.2% | 0.00% | -25.0% |
Q1 2023 | $17,685,131 | -3.0% | 488,135 | -4.5% | 0.00% | 0.0% |
Q4 2022 | $18,228,262 | +3.3% | 511,025 | -2.0% | 0.00% | 0.0% |
Q3 2022 | $17,643,000 | +19.3% | 521,227 | +1.9% | 0.00% | +33.3% |
Q2 2022 | $14,792,000 | -16.1% | 511,504 | -6.2% | 0.00% | 0.0% |
Q1 2022 | $17,626,000 | +10.6% | 545,371 | -0.2% | 0.00% | 0.0% |
Q4 2021 | $15,939,000 | -3.2% | 546,622 | -11.4% | 0.00% | 0.0% |
Q3 2021 | $16,458,000 | -12.3% | 617,120 | +1.3% | 0.00% | -25.0% |
Q2 2021 | $18,760,000 | +9.1% | 609,294 | -7.2% | 0.00% | 0.0% |
Q1 2021 | $17,192,000 | +4.1% | 656,678 | +0.1% | 0.00% | 0.0% |
Q4 2020 | $16,512,000 | +19.9% | 656,251 | -0.7% | 0.00% | +33.3% |
Q3 2020 | $13,777,000 | -15.5% | 661,107 | -3.7% | 0.00% | -25.0% |
Q2 2020 | $16,298,000 | +30.7% | 686,219 | -1.0% | 0.00% | 0.0% |
Q1 2020 | $12,471,000 | -26.8% | 693,226 | -3.5% | 0.00% | 0.0% |
Q4 2019 | $17,048,000 | -37.8% | 718,719 | -27.9% | 0.00% | -50.0% |
Q3 2019 | $27,410,000 | -19.5% | 997,458 | -3.1% | 0.01% | -11.1% |
Q2 2019 | $34,061,000 | -6.6% | 1,029,359 | -1.1% | 0.01% | -10.0% |
Q1 2019 | $36,457,000 | -9.1% | 1,040,439 | -13.8% | 0.01% | -23.1% |
Q4 2018 | $40,086,000 | -36.6% | 1,206,632 | -3.9% | 0.01% | -18.8% |
Q3 2018 | $63,238,000 | -26.9% | 1,255,961 | -13.1% | 0.02% | -33.3% |
Q2 2018 | $86,466,000 | +27.2% | 1,444,720 | -2.7% | 0.02% | +26.3% |
Q1 2018 | $67,971,000 | +19.5% | 1,484,099 | +3.9% | 0.02% | +26.7% |
Q4 2017 | $56,903,000 | -4.1% | 1,427,928 | -3.7% | 0.02% | -6.2% |
Q3 2017 | $59,321,000 | -11.0% | 1,483,046 | -4.1% | 0.02% | -15.8% |
Q2 2017 | $66,646,000 | +27.6% | 1,546,329 | -7.3% | 0.02% | +35.7% |
Q1 2017 | $52,236,000 | +30.0% | 1,668,864 | +4.9% | 0.01% | +16.7% |
Q4 2016 | $40,167,000 | -4.1% | 1,590,780 | -6.1% | 0.01% | 0.0% |
Q3 2016 | $41,892,000 | +23.9% | 1,694,026 | +2.1% | 0.01% | +20.0% |
Q2 2016 | $33,806,000 | +79.4% | 1,659,604 | +34.3% | 0.01% | +66.7% |
Q1 2016 | $18,847,000 | +130.3% | 1,235,769 | +103.0% | 0.01% | +200.0% |
Q4 2015 | $8,183,000 | +4.2% | 608,894 | +8.8% | 0.00% | 0.0% |
Q3 2015 | $7,850,000 | +22.9% | 559,492 | +48.7% | 0.00% | 0.0% |
Q2 2015 | $6,387,000 | +308.1% | 376,192 | +190.5% | 0.00% | – |
Q1 2015 | $1,565,000 | +47.6% | 129,501 | +1.4% | 0.00% | – |
Q4 2014 | $1,060,000 | -15.1% | 127,692 | -11.1% | 0.00% | – |
Q3 2014 | $1,248,000 | -54.3% | 143,608 | -42.4% | 0.00% | – |
Q2 2014 | $2,732,000 | +292.5% | 249,492 | +220.4% | 0.00% | – |
Q1 2014 | $696,000 | +50.3% | 77,873 | +26.7% | 0.00% | – |
Q4 2013 | $463,000 | -45.1% | 61,474 | -46.6% | 0.00% | – |
Q3 2013 | $844,000 | +83.9% | 115,098 | +61.2% | 0.00% | – |
Q2 2013 | $459,000 | – | 71,420 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 297,500 | $17,478,000 | 3.94% |
ASHFORD CAPITAL MANAGEMENT INC | 1,124,405 | $36,341,000 | 3.91% |
ARMISTICE CAPITAL, LLC | 3,100,000 | $100,192,000 | 1.94% |
S&T BANK/PA | 316,326 | $10,224,000 | 1.54% |
Bruce & Co., Inc. | 222,105 | $7,178,000 | 1.47% |
MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 379,875 | $12,278,000 | 1.36% |
RICE HALL JAMES & ASSOCIATES, LLC | 854,949 | $27,632,000 | 1.10% |
Soleus Capital Management, L.P. | 251,000 | $8,112,000 | 1.05% |
Parkman Healthcare Partners LLC | 108,954 | $3,521,000 | 1.03% |
Aristotle Capital Boston, LLC | 1,258,067 | $40,661,000 | 1.03% |